| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA2179371
Max Phase: Preclinical
Molecular Formula: C19H35O5P
Molecular Weight: 374.46
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CCCCCCCCCC[C@@H]1CC[P@@](=O)(OC)OC(C)=C1C(=O)OC
Standard InChI: InChI=1S/C19H35O5P/c1-5-6-7-8-9-10-11-12-13-17-14-15-25(21,23-4)24-16(2)18(17)19(20)22-3/h17H,5-15H2,1-4H3/t17-,25-/m1/s1
Standard InChI Key: NHTZROPHLCBBHP-CRICUBBOSA-N
Associated Targets(Human)
PNLIP Tclin Pancreatic lipase (198 Activities)
Associated Targets(non-human)
POSSIBLE LYSOPHOSPHOLIPASE (22 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
LIPF Gastric triacylglycerol lipase (84 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
PNLIPRP2 Pancreatic lipase-related protein 2 (70 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CUT1 Cutinase 1 (30 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Mycobacterium tuberculosis H37Rv (422 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
RAW264.7 (28094 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Mycobacteroides abscessus (2066 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 374.46 | Molecular Weight (Monoisotopic): 374.2222 | AlogP: 5.84 | #Rotatable Bonds: 11 |
| Polar Surface Area: 61.83 | Molecular Species: | HBA: 5 | HBD: 0 |
| #RO5 Violations: 1 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.69 | CX LogD: 4.69 |
| Aromatic Rings: 0 | Heavy Atoms: 25 | QED Weighted: 0.26 | Np Likeness Score: 0.32 |
References
| 1. Point V, Malla RK, Diomande S, Martin BP, Delorme V, Carriere F, Canaan S, Rath NP, Spilling CD, Cavalier JF.. (2012) Synthesis and kinetic evaluation of cyclophostin and cyclipostins phosphonate analogs as selective and potent inhibitors of microbial lipases., 55 (22): [PMID:23095026] [10.1021/jm301216x] |
| 2. Point V, Malla RK, Carrière F, Canaan S, Spilling CD, Cavalier JF.. (2013) Enantioselective inhibition of microbial lipolytic enzymes by nonracemic monocyclic enolphosphonate analogues of cyclophostin., 56 (11): [PMID:23651298] [10.1021/jm4000787] |
| 3. Cavalier JF, Spilling CD, Durand T, Camoin L, Canaan S.. (2021) Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery., 209 [PMID:33071055] [10.1016/j.ejmech.2020.112908] |
Source
Source(1):